CRMP2 Antibody [K16M14] Datasheet

Biological Description

Specificity	CRMP2 Antibody [K16M14] detects endogenous levels of total CRMP2 protein.
Background	CRMP2 (collapsin response mediator protein‑2, also known as DPYSL2) is a cytosolic phosphoprotein of the CRMP family that is highly enriched in the developing and adult nervous system and functions as a multifunctional adaptor that links extracellular guidance and neurotrophic cues to intracellular cytoskeletal remodeling, vesicle trafficking, and channel regulation. The protein forms homo‑ and hetero‑tetramers with other CRMPs and contains an N‑terminal globular domain with binding surfaces for tubulin and regulatory enzymes and a C‑terminal flexible tail that carries multiple phosphorylation motifs for kinases such as Cdk5 and GSK3β, oxidation‑sensitive cysteines, and other post‑translational modification sites that tune its activity and subcellular localization. CRMP2 associates with tubulin heterodimers and promotes microtubule polymerization and stabilization, and this activity supports axon specification, elongation, and branching, the multipolar‑to‑bipolar transition of migrating neurons, and the polarized delivery of cargoes along axons, while simultaneous interactions with kinesin‑1, dynein, and endocytic machinery link CRMP2 to axonal transport, protein endocytosis, and recycling of membrane receptors and channels. The protein also participates in presynaptic and postsynaptic organization by regulating vesicle trafficking and synaptic assembly and by controlling the surface density and cycling of voltage‑gated calcium and sodium channels, which positions CRMP2 as a modulator of neuronal excitability and neurotransmitter release in addition to its structural roles in neurite architecture. CRMP2 activity is strongly governed by hierarchical phosphorylation and other modifications: Cdk5‑primed and GSK3β‑mediated phosphorylation at defined C‑terminal residues weakens binding to tubulin and motor proteins and shifts CRMP2 from a growth‑promoting to a growth‑inhibiting state, while dephosphorylation restores interaction with the cytoskeleton and transport complexes, integrating upstream signals from semaphorin–plexin/neuropilin pathways, neurotrophins, and other regulators into precise changes in neurite outgrowth, branching, and guidance. In the mature brain CRMP2 continues to influence synaptic stability and plasticity through effects on microtubule dynamics within dendrites and axon terminals and through regulation of vesicle cycling and receptor trafficking, and mapping of the CRMP2 interactome reveals connections to proteins that orchestrate actin remodeling, endocytosis, and presynaptic release, extending its impact beyond classical axon guidance. Dysregulated CRMP2 expression, phosphorylation, truncation, or mislocalization associates with a wide spectrum of neurological and psychiatric conditions, including Alzheimer’s disease, temporal lobe epilepsy, neuropathic pain, and schizophrenia, where hyperphosphorylated CRMP2 accumulates in neurofibrillary tangles together with tau and SRA1/WAVE1 complexes and correlates with synaptic and structural deficits, and where altered channel trafficking and cytoskeletal control contribute to aberrant excitability and network function.

Specificity

CRMP2 Antibody [K16M14] detects endogenous levels of total CRMP2 protein.

Background

CRMP2 (collapsin response mediator protein‑2, also known as DPYSL2) is a cytosolic phosphoprotein of the CRMP family that is highly enriched in the developing and adult nervous system and functions as a multifunctional adaptor that links extracellular guidance and neurotrophic cues to intracellular cytoskeletal remodeling, vesicle trafficking, and channel regulation. The protein forms homo‑ and hetero‑tetramers with other CRMPs and contains an N‑terminal globular domain with binding surfaces for tubulin and regulatory enzymes and a C‑terminal flexible tail that carries multiple phosphorylation motifs for kinases such as Cdk5 and GSK3β, oxidation‑sensitive cysteines, and other post‑translational modification sites that tune its activity and subcellular localization. CRMP2 associates with tubulin heterodimers and promotes microtubule polymerization and stabilization, and this activity supports axon specification, elongation, and branching, the multipolar‑to‑bipolar transition of migrating neurons, and the polarized delivery of cargoes along axons, while simultaneous interactions with kinesin‑1, dynein, and endocytic machinery link CRMP2 to axonal transport, protein endocytosis, and recycling of membrane receptors and channels. The protein also participates in presynaptic and postsynaptic organization by regulating vesicle trafficking and synaptic assembly and by controlling the surface density and cycling of voltage‑gated calcium and sodium channels, which positions CRMP2 as a modulator of neuronal excitability and neurotransmitter release in addition to its structural roles in neurite architecture. CRMP2 activity is strongly governed by hierarchical phosphorylation and other modifications: Cdk5‑primed and GSK3β‑mediated phosphorylation at defined C‑terminal residues weakens binding to tubulin and motor proteins and shifts CRMP2 from a growth‑promoting to a growth‑inhibiting state, while dephosphorylation restores interaction with the cytoskeleton and transport complexes, integrating upstream signals from semaphorin–plexin/neuropilin pathways, neurotrophins, and other regulators into precise changes in neurite outgrowth, branching, and guidance. In the mature brain CRMP2 continues to influence synaptic stability and plasticity through effects on microtubule dynamics within dendrites and axon terminals and through regulation of vesicle cycling and receptor trafficking, and mapping of the CRMP2 interactome reveals connections to proteins that orchestrate actin remodeling, endocytosis, and presynaptic release, extending its impact beyond classical axon guidance. Dysregulated CRMP2 expression, phosphorylation, truncation, or mislocalization associates with a wide spectrum of neurological and psychiatric conditions, including Alzheimer’s disease, temporal lobe epilepsy, neuropathic pain, and schizophrenia, where hyperphosphorylated CRMP2 accumulates in neurofibrillary tangles together with tau and SRA1/WAVE1 complexes and correlates with synaptic and structural deficits, and where altered channel trafficking and cytoskeletal control contribute to aberrant excitability and network function.

Usage Information

Application

WB, IP, IHC, IF, FCM

Dilution

WB	IP	IHC	IF	FCM
1:1000	1:30	1:5000	1:1000	1:5000

Reactivity

Human, Mouse, Rat

Source

Rabbit Monoclonal Antibody

MW

29 kDa

Storage Buffer

PBS, pH 7.2+50% Glycerol+0.05% BSA+0.01% NaN3

Storage
(from the date of receipt)

-20°C (avoid freeze-thaw cycles), 2 years

References

https://pubmed.ncbi.nlm.nih.gov/24402611/
https://pubmed.ncbi.nlm.nih.gov/21271304/

Application Data

WB

Validated by Selleck

Lane 1: SH-SY5Y, Lane 2: Hela, Lane 3: NIH/3T3, Lane 4: C6